Eugene Scobey, MD
Hospitalist · Memphis, TNNPI 1750493474
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,112 of the $6,097 with a category attached, or 67.4%. Novartis accounts for 86.6% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $5,492 and has fallen 99.6% since, to $21 in 2025. Among hospitalist clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 15 payments — averaging $406.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$5K
- Novo Nordisk$205
- Eisai Inc.$125
- Pfizer$121
- Johnson & Johnson$110
- Portola Pharmaceuticals, LLC$109
- plus $147 from 3 others
What the payments were for
- Consulting fees$4,11267%
- Travel & lodging$91315%
- Food & beverage$1,07118%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 6 | $5,280 |
| Novo Nordisk | 2 | $205 |
| Eisai Inc. | 1 | $125 |
| Pfizer | 1 | $121 |
| Johnson & Johnson | 1 | $110 |
| Portola Pharmaceuticals, LLC | 1 | $109 |
| GSK | 1 | $103 |
| Gilead | 1 | $24 |
| Abbott | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,097 in reported general payments places this provider in the 95th percentile of 349 hospitalist providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 65 | $415 |
| Donepezil Hcl | 59 | $277 |
| Metoprolol Succinate | 53 | $276 |
| Amlodipine Besylate | 66 | $262 |
| Levothyroxine Sodium | 53 | $244 |
| Tamsulosin Hcl | 53 | $243 |
| Simvastatin | 52 | $223 |
| Levocetirizine Dihydrochloride | 44 | $222 |
| Bethanechol Chloride | 22 | $215 |
| Fluphenazine Hcl | 52 | $190 |
| Hydralazine Hcl | 16 | $150 |
| Carvedilol | 17 | $49 |
Paid to pharmacies, not to this prescriber.
Other hospitalist in Memphis
- Ankur SethMemphis$13K
- Roshan BistaMemphis$4K
- Oladimeji LanadeMemphis$2K
- Daniel WellsMemphis$1K
- Srishti SareenMemphis$960
- Gerald OnuohaNashville$37K
- Sunil KripalaniNashville$23K
- Monico BanezJackson$6K
- Omar AlsharifKnoxville$6K
- Matthew JosephNashville$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.